Genelux Prices $20M Common Stock Offering at $3.00 Per Share with 30-Day Overallotment Option
Genelux Corporation has priced an underwritten offering of 6,666,667 common shares at $3.00 each, raising approximately $20.0 million before expenses. The company granted a 30-day option for underwriters to purchase up to an additional 1,000,000 shares, with net proceeds earmarked for R&D, clinical trials, capital expenditures and working capital.
1. Underwritten Offering Priced to Raise $20 Million
Genelux Corporation has successfully priced an underwritten public offering of 6,666,667 shares of its common stock at $3.00 per share, generating gross proceeds of approximately $20.0 million before underwriting discounts, commissions and estimated offering expenses. The company has also granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares on the same terms. Lucid Capital Markets served as sole book-running manager. The offering is expected to close on or about January 9, 2026, subject to customary closing conditions.
2. Strategic Deployment of Net Proceeds
Genelux plans to allocate the net proceeds from the offering toward general corporate purposes, with a primary focus on advancing its Olvi-Vec oncolytic immunotherapy programs. Specifically, funds will support ongoing Phase 3 and Phase 2 registrational trials in platinum-resistant ovarian cancer and non-small cell lung cancer, respectively, as well as dose-selection activities in a Phase 1b/2 small-cell lung cancer trial in China. Additional proceeds may be directed to research and development expenses, clinical trial costs, capital expenditures and working capital to reinforce the company’s late-stage pipeline.
3. Regulatory and Shelf Registration Background
The shares were offered under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission on February 2, 2024 and declared effective on February 13, 2024. A preliminary prospectus supplement describing the final terms of the offering has been filed and is available on the SEC’s website. Upon completion of the offering, investors may obtain copies of the final prospectus supplement and accompanying prospectus from Lucid Capital Markets, LLC.
4. Reinforcing Late-Stage Immuno-Oncology Programs
Genelux is focused on next-generation oncolytic immunotherapies based on its proprietary CHOICE™ platform. Olvi-Vec, the company’s lead candidate, is currently being evaluated in two U.S.-based trials (OnPrime/GOG-3076 Phase 3 in platinum-resistant/refractory ovarian cancer and VIRO-25 Phase 2 in non-small cell lung cancer) and a China-based Phase 1b/2 dose-selection study in recurrent small-cell lung cancer. The fresh capital positions Genelux to accelerate enrollment, data readouts and potential regulatory submissions across these critical late-stage studies.